1355 GMT - The recent share selloff following disappointing trial results of Novo Nordisk's experimental anti-obesity treatment is overdone, UBS analyst Jo Walton writes. "The CagriSema phase 3 data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes." UBS says Novo remains the most exciting growth story in European pharmaceuticals and is well placed to continue to benefit from the high demand for GLP-1 medications near-term. UBS upgrades Novo Nordisk to buy from neutral and lowers its price target to 750 Danish kroner from 1,100 kroner. Shares rise 3.1% higher to 621.50 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 08, 2025 08:55 ET (13:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。